Beam Therapeutics Inc [BEAM] stock is trading at $29.01, up 8.04%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BEAM shares have gain 3.87% over the last week, with a monthly amount glided 18.46%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on November 06, 2024, when Leerink Partners upgraded its rating to a Outperform and also boosted its price target to $39 from $27. On July 23, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $80 on the stock. JP Morgan upgraded its rating to a Overweight and increased its price target to $40 on January 29, 2024. BofA Securities downgraded its rating to a Neutral but $35 remained the price target by the analyst firm on December 15, 2023. Jefferies downgraded its rating to Hold for this stock on December 08, 2023, and downed its price target to $30. In a note dated October 20, 2023, Leerink Partners downgraded an Market Perform rating on this stock and revised its target price from $75 to $20.
Beam Therapeutics Inc [BEAM] stock has fluctuated between $20.84 and $49.50 over the past year. Currently, Wall Street analysts expect the stock to reach $55 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $29.01 at the most recent close of the market. An investor can expect a potential return of 89.59% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
Beam Therapeutics Inc [NASDAQ:BEAM] reported sales of 349.64M for the trailing twelve months, which represents a drop of -17.01%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.41%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.16 and Total Capital is -0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.43 points at the first support level, and at 25.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.90, and for the 2nd resistance point, it is at 30.78.
Ratios To Look Out For
For context, Beam Therapeutics Inc’s Current Ratio is 5.69. In addition, the Quick Ratio stands at 5.69 and the Cash Ratio stands at 1.38. Considering the valuation of this stock, the price to sales ratio is 7.42, the price to book ratio is 3.03.
Transactions by insiders
Recent insider trading involved Ciaramella Giuseppe, President, that happened on Nov 06 ’24 when 51110.0 shares were sold. President, Ciaramella Giuseppe completed a deal on Oct 14 ’24 to sell 51110.0 shares. Meanwhile, Officer Giuseppe Ciaramella bought 0.1 million shares on Oct 14 ’24.
